Literature DB >> 2002640

Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels.

S Heidenreich1, K H Rahn, W Zidek.   

Abstract

The contractile properties of recombinant human erythropoietin (rHuEPO) on isolated resistance vessels of renal and mesenteric vascular beds were studied in an in vitro model using a small vessel myograph. Under isometric conditions, rHuEPO caused a contraction of this vasculature in a concentration range between 10 U/ml and 200 U/ml. A maximal active wall tension of 1.52 +/- 0.19 mN/mm was obtained under a rHuEPO dose of 200 U/ml. In Ca2+ free solution, the pressor response to high rHuEPO-concentrations was attenuated, and the response to low rHuEPO concentrations was abolished. In the presence of verapamil, phentolamine and saralasin, rHuEPO-induced contractions were not affected significantly. A dose-dependent vasodilatation of mounted vasculature to acetylcholine (ACh) indicated that endothelium remained intact in our preparations. rHuEPO-induced vessel contraction was not abrogated after an enzymatical removal of endothelium by collagenase, confirming that the described contractile responses are endothelial independent. These findings suggest that a direct vasopressor effect of rHuEPO on proximal resistance vessels may contribute to development of hypertension seen in rHuEPO-treated hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2002640     DOI: 10.1038/ki.1991.31

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  23 in total

1.  Advanced heart failure and nocturnal hypoxaemia due to central sleep apnoea are associated with increased serum erythropoietin.

Authors:  Andrew D Calvin; Virend K Somers; David P Steensma; Jose A Rio Perez; Christelle van der Walt; Jennifer M Fitz-Gibbon; Christopher G Scott; Lyle J Olson
Journal:  Eur J Heart Fail       Date:  2010-04       Impact factor: 15.534

Review 2.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

3.  Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock.

Authors:  F Squadrito; D Altavilla; G Squadrito; G M Campo; M Arlotta; C Quartarone; A Saitta; A P Caputi
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

Review 4.  Hypertension in hemodialysis patients.

Authors:  M Rahman; M C Smith
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

5.  Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury.

Authors:  Murat Celik; Necati Gökmen; Serhat Erbayraktar; Mustafa Akhisaroglu; Selman Konakc; Cagnur Ulukus; Sermin Genc; Kursad Genc; Emel Sagiroglu; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

Review 6.  Effects of recombinant human erythropoietin in normal humans.

Authors:  Carsten Lundby; Niels Vidiendal Olsen
Journal:  J Physiol       Date:  2010-08-31       Impact factor: 5.182

7.  The effect of recombinant human erythropoietin on cardiovascular responses to postural stress in dialysis patients.

Authors:  M E Rogerson; C H Kong; B Leaker; F D Thompson; E Oviasu; G H Neild
Journal:  Clin Auton Res       Date:  1993-08       Impact factor: 4.435

8.  Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

Authors:  Thomas R Coleman; Christof Westenfelder; Florian E Tögel; Ying Yang; Zhuma Hu; Leanne Swenson; Henri G D Leuvenink; Rutger J Ploeg; Livius V d'Uscio; Zvonimir S Katusic; Pietro Ghezzi; Adriana Zanetti; Kenneth Kaushansky; Norma E Fox; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

9.  Circulating levels of erythropoietin and its relation to arterial stiffness in patients with hypertension.

Authors:  Omer Gedikli; Abdulkadir Kiris; Caner Karahan
Journal:  Int J Clin Exp Med       Date:  2013-09-01

10.  Subcutaneous recombinant erythropoietin in preterminal renal insufficiency.

Authors:  C Van Geet; M Van Dyck; W Proesmans
Journal:  Eur J Pediatr       Date:  1994-02       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.